Unknown

Dataset Information

0

The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial.


ABSTRACT:

Introduction

Helicobacter pylori eradication therapy may lead to the perturbation of gut microbiota. We aim to investigate the impact of probiotics on eradication rate and gut microbiota during eradication therapy.

Methods

A total of 162 patients receiving bismuth quadruple therapy were enrolled and randomly assigned to groups given probiotics (n = 83) or placebo (n = 79) for 4 weeks. Fecal samples were collected before treatment and 2, 4, 6, and 8 weeks after eradication therapy. Gut microbiota was analyzed by 16S rRNA high-throughput sequencing.

Results

The eradication rates in the placebo and probiotics group were 82.43% and 87.01%, respectively (P > 0.05). Compared with baseline, alpha and beta diversity was significantly altered 2 weeks after eradication in both groups, which was restored at week 8. There were no significant differences in diversity between the two groups. H. pylori eradication therapy resulted in enrichment of some detrimental bacteria taxa such as Shigella, Klebsiella, and Streptococcus, while probiotics supplementation could rapidly restore these taxa levels after eradication and increase the taxa of Bacillus and Lactobacillales. Functional analysis revealed that lipopolysaccharide biosynthesis and polymyxin resistance pathways were significantly enriched after eradication, while probiotics supplementation mainly enriched the cofactors and vitamins metabolism pathways. Increased relative abundances of Roseburia and Dialister were associated with the positive eradication outcome.

Conclusions

Probiotics supplementation might help to construct a beneficial profile of gut microbiota after eradication therapy. Specific bacteria taxa are associated with H. pylori eradication outcome. These findings may be of value in rational use of probiotics during H. pylori eradication.

Trial registration

Chinese Clinical Trial Registry, ChiCTR1900022116.

SUBMITTER: Tang B 

PROVIDER: S-EPMC7955021 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4603068 | biostudies-literature
| PRJEB39893 | ENA
| S-EPMC4217763 | biostudies-literature
| S-EPMC7214376 | biostudies-literature
| S-EPMC8387937 | biostudies-literature
| S-EPMC10577438 | biostudies-literature
| S-EPMC6718723 | biostudies-literature
| S-EPMC6161473 | biostudies-literature
| S-EPMC8678011 | biostudies-literature
| S-EPMC10722661 | biostudies-literature